Literature DB >> 12524445

Dependence of purinergic P2X receptor activity on ectodomain structure.

Mu-Lan He1, Hana Zemkova, Stanko S Stojilkovic.   

Abstract

Purinergic receptors (P2XRs) activate and desensitize in response to the binding of extracellular nucleotides in a receptor- and ligand-specific manner, but the structural bases of their ligand preferences and channel kinetics have been incompletely characterized. Here we tested the hypothesis that affinity of agonists for binding domain accounts for a ligand-specific desensitization pattern. We generated chimeras using receptors with variable sensitivity to ATP in order: P2X(4)R > P2X(2a)R = P2X(2b)R P2X(7)R. Chimeras having the ectodomain Ile(66)-Tyr(310) sequence of P2X(2)R and Val(61)-Phe(313) sequence of P2X(7)R in the backbone of P2X(4)R were expressed but were non-functioning channels. P2X(2a) + X(4)R and P2X(2b) + X(4)R chimeras having the Val(66)-Tyr(315) ectodomain sequence of P2X(4)R in the backbones of P2X(2a)R and P2X(2b)R were functional and exhibited increased sensitivity to ligands as compared with both parental receptors. These chimeras also desensitized faster than parental receptors and in a ligand-nonspecific manner. However, like parental P2X(2b)R and P2X(2a)R, chimeric P2X(2b) + X(4)R desensitized more rapidly than P2X(2a) + X(4)R, and the rate of desensitization of P2X(2a)+X(4)R increased by substituting its Arg(371)-Pro(376) intracellular C-terminal sequence with the Glu(376)-Gly(381) sequence of P2X(4)R. These results indicate the relevance of interaction between the ectodomain and flanking regions around the transmembrane domains on ligand potency and receptor activation. Furthermore, the ligand potency positively correlates with the rate of receptor desensitization but does not affect the C-terminal-specific pattern of desensitization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12524445     DOI: 10.1074/jbc.M209094200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

Review 1.  Activation and regulation of purinergic P2X receptor channels.

Authors:  Claudio Coddou; Zonghe Yan; Tomas Obsil; J Pablo Huidobro-Toro; Stanko S Stojilkovic
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

Review 2.  Structural insights into the function of P2X4: an ATP-gated cation channel of neuroendocrine cells.

Authors:  Stanko S Stojilkovic; Zonghe Yan; Tomas Obsil; Hana Zemkova
Journal:  Cell Mol Neurobiol       Date:  2010-11-25       Impact factor: 5.046

3.  Role of domain calcium in purinergic P2X2 receptor channel desensitization.

Authors:  Claudio Coddou; Zonghe Yan; Stanko S Stojilkovic
Journal:  Am J Physiol Cell Physiol       Date:  2015-02-11       Impact factor: 4.249

4.  Identification of P2X(4) receptor transmembrane residues contributing to channel gating and interaction with ivermectin.

Authors:  Irena Jelínkova; Vojtech Vávra; Marie Jindrichova; Tomas Obsil; Hana W Zemkova; Hana Zemkova; Stanko S Stojilkovic
Journal:  Pflugers Arch       Date:  2008-04-22       Impact factor: 3.657

5.  P2X receptor chimeras highlight roles of the amino terminus to partial agonist efficacy, the carboxyl terminus to recovery from desensitization, and independent regulation of channel transitions.

Authors:  Rebecca C Allsopp; Louise K Farmer; Alistair G Fryatt; Richard J Evans
Journal:  J Biol Chem       Date:  2013-06-05       Impact factor: 5.157

6.  P2X4 Receptor in Silico and Electrophysiological Approaches Reveal Insights of Ivermectin and Zinc Allosteric Modulation.

Authors:  Verónica Latapiat; Felipe E Rodríguez; Francisca Godoy; Felipe A Montenegro; Nelson P Barrera; Juan P Huidobro-Toro
Journal:  Front Pharmacol       Date:  2017-12-15       Impact factor: 5.810

7.  Opposing Roles of Calcium and Intracellular ATP on Gating of the Purinergic P2X2 Receptor Channel.

Authors:  Milos B Rokic; Patricio Castro; Elias Leiva-Salcedo; Melanija Tomic; Stanko S Stojilkovic; Claudio Coddou
Journal:  Int J Mol Sci       Date:  2018-04-11       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.